BioNTech (BNTX) Competitors

BioNTech (NASDAQ:BNTX) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, community ranking, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Do analysts rate BNTX or GSK?

BioNTech currently has a consensus target price of $138.79, indicating a potential upside of 35.88%. GSK has a consensus target price of $43.25, indicating a potential upside of 29.65%. Given BioNTech's stronger consensus rating and higher probable upside, research analysts plainly believe BioNTech is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.81
GSK	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	2.60

Which has more volatility and risk, BNTX or GSK?

BioNTech has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Does the media favor BNTX or GSK?

In the previous week, BioNTech had 10 more articles in the media than GSK. MarketBeat recorded 30 mentions for BioNTech and 20 mentions for GSK. GSK's average media sentiment score of 0.60 beat BioNTech's score of 0.31 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	5 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
GSK	13 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has preferable earnings and valuation, BNTX or GSK?

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.04B	8.05	$1.01B	-$2.10	-48.64
GSK	$37.71B	1.83	$6.13B	$1.54	21.66

Do institutionals and insiders have more ownership in BNTX or GSK?

15.5% of BioNTech shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the MarketBeat Community favor BNTX or GSK?

GSK received 678 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 56.92% of users gave GSK an outperform vote while only 45.48% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
BioNTech	Outperform Votes 136 45.48%	Underperform Votes 163 54.52%
GSK	Outperform Votes 814 56.92%	Underperform Votes 616 43.08%

Is BNTX or GSK a better dividend stock?

BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.5%. GSK pays an annual dividend of $1.53 per share and has a dividend yield of 4.6%. BioNTech pays out -72.9% of its earnings in the form of a dividend. GSK pays out 99.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Is BNTX or GSK more profitable?

GSK has a net margin of 7.97% compared to BioNTech's net margin of -15.16%. GSK's return on equity of 50.62% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-15.16%	-2.35%	-2.05%
GSK	7.97%	50.62%	11.54%

Summary

GSK beats BioNTech on 14 of the 21 factors compared between the two stocks.